NCT02386306View on ClinicalTrials.gov

Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

GC021109

OTHER

Placebo

Trial Locations (5)

32806

Compass Research, Orlando

33009

MD Clinical, Hallandale

33064

Quantum laboratories / Memory Disorder Center, Deerfield Beach

33449

Alzheimer's Research and Treatment Center, Lake Worth

90806

Collaborative Neuroscience Network, Long Beach

Sponsors

Lead Sponsor

GliaCure, Inc.
All Listed Sponsors
lead

GliaCure, Inc.

INDUSTRY